Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

Presentation TCT 2024

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Presenter: Deepak Bhatt

October 29, 2024

Presentation TCT 2024

TCT 502: Nicotine Inhibits Re-Endothelialization and Promotes Inflammation and Neoatherosclerosis After Drug-Eluting Stent Implantation in a Swine Model

Presenter: Seok Oh

October 29, 2024

Presentation TCT 2024

Inflammation- Current and Emerging Therapeutic Landscape

Presenter: Deepak Bhatt

October 29, 2024

Presentation TCT 2024

What Comes Next? Role of Inflammation on AMI

Presenter: Kevin Bainey

October 28, 2024

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

Caitlin E. Cox

October 28, 2024

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

Caitlin E. Cox

October 25, 2023

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

Presentation TCT 2019

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2019

Tackling Inflammation: Novel Targets

Presenter: Wolfgang Koenig

September 26, 2019

Presentation TCT 2019

LP(a): Not So Little Anymore

Presenter: Roberta Rossini

September 26, 2019

Presentation TCT 2019

Don’t Forget About Your HDL: The AEGIS Program

Presenter: C. Michael Gibson

September 26, 2019

Presentation TCT 2019

Role of PCSK9 Inhibitors Post-PCI and ACS

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2019

Loading Dose Statin Prior PCI: Is There a Role For It?

Presenter: Renato Lopes

September 26, 2019

News Conference News TCT 2018

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

Michael O'Riordan

September 25, 2018

Presentation TCT 2016

YELLOW II: Relationship of Serial Change in Plaque Morphology of Obstructive Non-Culprit Lesions to HDL Efflux, Inflammation and Transcriptome Perturbations in Response to High-Dose Statin Therapy

Presenter: Spencer B. King III, Jagat Narula, Annapoorna Kini

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Advertisement

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

TCT 502: Nicotine Inhibits Re-Endothelialization and Promotes Inflammation and Neoatherosclerosis After Drug-Eluting Stent Implantation in a Swine Model

Inflammation- Current and Emerging Therapeutic Landscape

What Comes Next? Role of Inflammation on AMI

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

Comparing DCBs in De Novo CAD: Drugs, Design Matter

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Tackling Inflammation: Novel Targets

LP(a): Not So Little Anymore

Don’t Forget About Your HDL: The AEGIS Program

Role of PCSK9 Inhibitors Post-PCI and ACS

Loading Dose Statin Prior PCI: Is There a Role For It?

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

YELLOW II: Relationship of Serial Change in Plaque Morphology of Obstructive Non-Culprit Lesions to HDL Efflux, Inflammation and Transcriptome Perturbations in Response to High-Dose Statin Therapy

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content